Browse CDH2

Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Cell membrane, sarcolemma Cell junction Cell surface Note=Colocalizes with TMEM65 at the intercalated disk in cardiomyocytes. Colocalizes with OBSCN at the intercalated disk and at sarcolemma in cardiomyocytes.
Domain PF00028 Cadherin domain
PF01049 Cadherin cytoplasmic region
PF08758 Cadherin prodomain like
Function

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density (By similarity).

> Gene Ontology
 
Biological Process GO:0001941 postsynaptic membrane organization
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0007009 plasma membrane organization
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0007416 synapse assembly
GO:0010001 glial cell differentiation
GO:0014013 regulation of gliogenesis
GO:0016055 Wnt signaling pathway
GO:0016339 calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0019827 stem cell population maintenance
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021987 cerebral cortex development
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030900 forebrain development
GO:0034330 cell junction organization
GO:0034332 adherens junction organization
GO:0042063 gliogenesis
GO:0042692 muscle cell differentiation
GO:0043113 receptor clustering
GO:0043410 positive regulation of MAPK cascade
GO:0044091 membrane biogenesis
GO:0044331 cell-cell adhesion mediated by cadherin
GO:0045216 cell-cell junction organization
GO:0048514 blood vessel morphogenesis
GO:0048854 brain morphogenesis
GO:0048872 homeostasis of number of cells
GO:0050803 regulation of synapse structure or activity
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051668 localization within membrane
GO:0060019 radial glial cell differentiation
GO:0060070 canonical Wnt signaling pathway
GO:0060563 neuroepithelial cell differentiation
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061351 neural precursor cell proliferation
GO:0070444 oligodendrocyte progenitor proliferation
GO:0070445 regulation of oligodendrocyte progenitor proliferation
GO:0071709 membrane assembly
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090002 establishment of protein localization to plasma membrane
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090150 establishment of protein localization to membrane
GO:0097091 synaptic vesicle clustering
GO:0097104 postsynaptic membrane assembly
GO:0097118 neuroligin clustering involved in postsynaptic membrane assembly
GO:0097119 postsynaptic density protein 95 clustering
GO:0097150 neuronal stem cell population maintenance
GO:0097479 synaptic vesicle localization
GO:0098727 maintenance of cell number
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:0099068 postsynapse assembly
GO:0099504 synaptic vesicle cycle
GO:0198738 cell-cell signaling by wnt
GO:1901626 regulation of postsynaptic membrane organization
GO:1902897 regulation of postsynaptic density protein 95 clustering
GO:1990778 protein localization to cell periphery
GO:2000177 regulation of neural precursor cell proliferation
GO:2000807 regulation of synaptic vesicle clustering
GO:2000809 positive regulation of synaptic vesicle clustering
Molecular Function GO:0008013 beta-catenin binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0045294 alpha-catenin binding
GO:0045295 gamma-catenin binding
Cellular Component GO:0005913 cell-cell adherens junction
GO:0005916 fascia adherens
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0014704 intercalated disc
GO:0015629 actin cytoskeleton
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0016342 catenin complex
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030027 lamellipodium
GO:0030055 cell-substrate junction
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0031252 cell leading edge
GO:0044291 cell-cell contact zone
GO:0044448 cell cortex part
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-418990: Adherens junctions interactions
R-HSA-375170: CDO in myogenesis
R-HSA-446728: Cell junction organization
R-HSA-1500931: Cell-Cell communication
R-HSA-421270: Cell-cell junction organization
R-HSA-1266738: Developmental Biology
R-HSA-525793: Myogenesis
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDH2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CDH2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21057494Castration-Resistant Prostate CarcinomaInhibit immunityIn vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression. N-cadherin-specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion.
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDH2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDH2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0790.918
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3470.822
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1110.932
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1760.793
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.860.536
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.4820.388
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5120.476
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5830.662
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4150.777
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1910.906
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1990.933
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0560.842
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDH2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.817.6-12.80.307
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDH2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDH2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDH2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDH2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDH2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDH2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDH2
Namecadherin 2, type 1, N-cadherin (neuronal)
Aliases CDHN; CD325; N-cadherin; NCAD; CDw325; N-cadherin 1; calcium-dependent adhesion protein, neuronal; neural ca ......
Chromosomal Location18q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDH2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.